{"filing":{"accession_number":"0001178913-26-003966","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"zk2635901.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003966/zk2635901.htm"},"events":[{"id":26293,"run_id":23884,"accession_number":"0001178913-26-003966","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Silexion disclosed an updated corporate presentation on August 10, 2026, containing an updated timeline for clinical testing and regulatory approval of its lead product candidate SIL 204. The presentation details the Phase 2/3 clinical trial initiated in July 2026, with specific milestones including Segment 1 completion expected Q2 2027, Segment 2 initiation Q3 2027, and Segment 3 initiation Q3 2030. This is a material operational/strategic disclosure regarding the company's clinical development program timeline and manufacturing collaborations with Catalent and Axolabs, which would affect a reasonable investor's assessment of the registrant's product development progress and commercialization pathway.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27359,"accession_number":"0001178913-26-003966","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Silexion disclosed an updated corporate presentation on August 10, 2026, containing an updated timeline for clinical testing and regulatory approval of its lead product candidate SIL 204. The presentation details the Phase 2/3 clinical trial initiated in July 2026, with specific milestones including Segment 1 completion expected Q2 2027, Segment 2 initiation Q3 2027, and Segment 3 initiation Q3 2030. This is a material operational/strategic disclosure regarding the company's clinical development program timeline and manufacturing collaborations with Catalent and Axolabs, which would affect a reasonable investor's assessment of the registrant's product development progress and commercialization pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:17:38.589605+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27359,"accession_number":"0001178913-26-003966","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Silexion disclosed an updated corporate presentation on August 10, 2026, containing an updated timeline for clinical testing and regulatory approval of its lead product candidate SIL 204. The presentation details the Phase 2/3 clinical trial initiated in July 2026, with specific milestones including Segment 1 completion expected Q2 2027, Segment 2 initiation Q3 2027, and Segment 3 initiation Q3 2030. This is a material operational/strategic disclosure regarding the company's clinical development program timeline and manufacturing collaborations with Catalent and Axolabs, which would affect a reasonable investor's assessment of the registrant's product development progress and commercialization pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:17:38.589605+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-08-10"}]}